New Flu Vaccine for Older Adults
New Flu Vaccine for Older Adults
針對年長者的流感新疫苗
Introduction
A group of experts says a new flu vaccine from Moderna is good. This vaccine is for adults aged 50 and older.
專家團隊表示 Moderna 研發的新型流感疫苗效果良好。此疫苗適用於 50 歲及以上的成年人。
Main Body
The company tested the vaccine on 40,000 people. It works 27% better than old vaccines. The experts want the government to allow it for people aged 50 to 64. People 65 and older can also use it, but the company must do more tests.
該公司在 4 萬人身上測試了此疫苗。其效果比舊款疫苗提升了 27%。專家希望政府允許 50 至 64 歲的人群使用。65 歲及以上的人亦可使用，但該公司必須進行更多測試。
This vaccine is faster to make. Old vaccines use eggs and take six months to make. This new vaccine takes only two or three months. This helps doctors fight the flu better.
此疫苗的生產速度較快。舊款疫苗使用雞蛋且需要六個月的製備時間。而新疫苗僅需兩到三個月。這有助於醫生更有效地對抗流感。
Some government leaders do not like this new technology. One leader stopped 500 million dollars for research. Also, the FDA does not have a permanent boss right now.
部分政府領導人並不認同這項新技術。一名領導人停止了 5 億美元的研究撥款。此外，FDA 目前缺乏一名正式的負責人。
Conclusion
The experts like the vaccine. Now, the FDA and the CDC must say yes before people can buy it.
專家們認可此疫苗。目前 FDA 與 CDC 必須核准後，民眾才能購買。
Vocabulary Learning
⏳ Comparing Time
Look at how we talk about how long things take. This is very useful for A2 daily conversations.
The Pattern:
Take + Amount of Time
- Old way: "Take six months"
- New way: "Take two or three months"
Why it matters: When you describe a process (like cooking, traveling, or working), use take.
Example: Walking to school → takes 10 minutes. Learning English → takes time.
⚡️ The "Better" Jump
In the text, we see: "It works 27% better than old vaccines."
To move from A1 to A2, stop saying "good" for everything. Use Better than to compare two things:
- Fast Faster than
- Good Better than
- Cheap Cheaper than
Quick Rule: [Thing A] + [Comparative Word] + than + [Thing B].
Modern vaccine is faster than old vaccine.
Vocabulary Learning
FDA Advisory Committee Supports Moderna's mRNA Flu Vaccine
FDA 諮詢委員會支持 Moderna 的 mRNA 流感疫苗
Introduction
The Vaccines and Related Biological Products Advisory Committee has unanimously recommended the approval of mFlusiva, an mRNA influenza vaccine created by Moderna for adults aged 50 and older.
疫苗及相關生物製品諮詢委員會一致建議批准 mFlusiva，這是一款由 Moderna 為 50 歲及以上成年人研發的 mRNA 流感疫苗。
Main Body
This recommendation comes after a large clinical trial with 40,000 participants, which showed that the vaccine was 27% more effective than standard flu shots. The committee suggested two different approval paths: full approval for people aged 50 to 64, and a faster, 'accelerated' path for those 65 and older, provided that more studies are done after the vaccine reaches the market. This decision follows a disagreement with the FDA, which had previously rejected the application because the trial did not compare the new vaccine to the high-dose shots usually given to elderly patients. However, Moderna argued that the FDA had previously agreed to the trial design and provided extra data to show the vaccine worked similarly to high-dose options.
此建議是在一項有 40,000 人參與的大型臨床試驗後提出的，結果顯示該疫苗比標準流感疫苗有效 27%。委員會建議了兩種不同的批准路徑：50 至 64 歲人士可獲得完全批准，而 65 歲及以上人士則可透過較快的「加速」路徑批准，前提是疫苗上市後須進行更多研究。此決定是在與 FDA 產生分歧後做出的，FDA 此前因試驗未將新疫苗與通常提供給高齡患者的高劑量疫苗進行比較而拒絕了申請。然而，Moderna 主張 FDA 此前已同意該試驗設計，並提供了額外數據證明該疫苗的效果與高劑量方案相似。
From a technical side, the mRNA platform is much faster to produce than traditional egg-based vaccines. While traditional methods take about six months, mRNA vaccines can be ready in two to three months. Consequently, this allows scientists to match the vaccine more accurately to the current flu strains. Despite these benefits, the political situation is difficult. Health Secretary Robert F. Kennedy Jr. has expressed doubts about mRNA technology and has already cancelled around $500 million in research funding. Furthermore, the FDA currently lacks permanent leaders in its vaccine division and commissioner's office, meaning temporary officials must make the final decision.
從技術層面來看，mRNA 平台的生產速度遠快於傳統的雞蛋疫苗。傳統方法約需六個月，而 mRNA 疫苗在兩到三個月內即可準備就緒。因此，這使得科學家能更準確地使疫苗對應當前的流感病毒株。儘管有這些優勢，但政治局勢十分困難。衛生部長 Robert F. Kennedy Jr. 對 mRNA 技術表示懷疑，並已取消了約 5 億美元的研究資金。此外，FDA 的疫苗部門和局長辦公室目前缺乏常任領導人，這意味著最終決定必須由臨時官員做出。
Conclusion
Although the advisory panel supports the vaccine, it will not be available until it receives formal FDA approval and a recommendation from the CDC, which is currently delayed by a court case.
雖然諮詢小組支持該疫苗，但在獲得 FDA 正式批准及 CDC 建議之前，該疫苗將無法上市，而目前正因一起法院訴訟而延遲。
Vocabulary Learning
⚡ The Power of 'Connecting Words' (Transitioning from A2 to B2)
At the A2 level, students often use simple sentences: "The vaccine is fast. The political situation is bad." To reach B2, you must glue these ideas together using Connectors. These words tell the reader how two ideas relate.
🛠️ The "Logic Glue" found in this text:
1. The Contrast (The "But" Upgrade) Instead of just using "but," this text uses:
- Despite ("Despite these benefits..."): Use this to show that one fact does not stop another from being true.
- Although ("Although the advisory panel supports..."): Use this to introduce a surprising contrast at the start of a sentence.
2. The Result (The "So" Upgrade) Instead of saying "so," look at:
- Consequently ("Consequently, this allows scientists..."): This is a formal way to say "because of this, the result is..."
3. The Addition (The "And" Upgrade) Instead of repeating "and," the author uses:
- Furthermore ("Furthermore, the FDA currently lacks..."): Use this when you are adding a second, often more serious, point to your argument.
💡 Quick B2 Shift
| A2 Style (Simple) | B2 Style (Connected) |
|---|---|
| It is fast. It is expensive. | Although it is fast, it is expensive. |
| I studied hard. I failed. | Despite studying hard, I failed. |
| The rain started. We went inside. | The rain started; consequently, we went inside. |
Coach's Tip: To sound like a B2 speaker, stop starting every sentence with a subject (I, The, It). Start your sentences with these connectors to guide your listener through your logic.
Vocabulary Learning
FDA Advisory Committee Endorsement of Moderna's mRNA-Based Influenza Vaccine
FDA 諮詢委員會支持 Moderna 的 mRNA 流感疫苗
Introduction
The Vaccines and Related Biological Products Advisory Committee has unanimously recommended the approval of mFlusiva, an mRNA influenza vaccine developed by Moderna for adults aged 50 and older.
疫苗及相關生物製品諮詢委員會已一致建議批准 mFlusiva，這是一款由 Moderna 開發，針對 50 歲及以上成年人的 mRNA 流感疫苗。
Main Body
The recommendation follows a late-stage clinical trial involving 40,000 participants, which indicated that the vaccine demonstrated a 27% increase in efficacy relative to standard influenza vaccinations. The committee proposed a bifurcated approval pathway: full licensure for the 50-64 age cohort and an accelerated pathway for those 65 and older, contingent upon the execution of post-market clinical trials. This distinction arises from a prior regulatory dispute wherein the FDA initially rejected the application on the grounds that the trial compared the candidate vaccine to standard-dose shots rather than the high-dose versions typically recommended for the elderly. Moderna countered this position by citing prior agency concurrence with the trial design and providing supplementary data showing antibody generation comparable to high-dose alternatives.
該建議基於一項涉及 4 萬名參與者的後期臨床試驗，結果顯示該疫苗的功效比標準流感疫苗提高 27%。委員會提出了一套分兩路徑的批准方案：50 至 64 歲年齡組別獲得正式許可，而 65 歲及以上者則採取加速審批路徑，前提是需執行上市後臨床試驗。這種區分源於先前的監管爭議，當時 FDA 最初拒絕申請，理由是該試驗將候選疫苗與標準劑量疫苗進行比較，而非通常建議老年人使用的高劑量版本。Moderna 則反駁此觀點，指出該機構先前已同意試驗設計，並提供補充數據證明其產生的抗體與高劑量替代方案相當。
From a technical perspective, the mRNA platform offers significant operational advantages over traditional egg-based manufacturing. The transition from strain selection to deployment is estimated at two to three months, whereas conventional methods require approximately six months. This temporal efficiency potentially allows for more precise alignment with circulating viral strains. However, the regulatory environment remains complex. The Department of Health and Human Services, under Secretary Robert F. Kennedy Jr., has expressed skepticism regarding mRNA technology, evidenced by the cancellation of approximately $500 million in research funding. Furthermore, the agency currently lacks permanent leadership in its vaccine division and commissioner's office, with acting officials overseeing the final determination.
從技術角度來看，mRNA 平台比傳統雞蛋製造法具有顯著的操作優勢。從菌株選擇到部署的預計時間為兩到三個月，而傳統方法則需要約六個月。這種時間上的效率，潛在上能讓疫苗與循環病毒株更精準地對接。然而，監管環境依然複雜。在部長 Robert F. Kennedy Jr. 領導下的衛生與公共服務部對 mRNA 技術表示懷疑，其證據在於取消了約 5 億美元的研究資助。此外，該機構目前在疫苗部門和局長辦公室缺乏永久領導層，目前由代理官員監督最終決定。
Conclusion
While the advisory panel has endorsed the vaccine, final availability depends on formal FDA approval and a recommendation from the CDC, the latter of which is currently delayed by judicial intervention.
雖然諮詢委員會已支持該疫苗，但最終的可用性仍取決於 FDA 的正式批准以及 CDC 的建議，而後者目前因司法干預而延遲。
Vocabulary Learning
The Architecture of 'Regulatory Hegemony' and Nominalization
To move from B2 to C2, a student must stop thinking in terms of actions and start thinking in terms of states and conceptual frameworks. The provided text is a masterclass in Nominalization—the process of turning verbs and adjectives into nouns to create an air of objective, institutional authority.
⚡ The C2 Pivot: From Action to Concept
Observe the transition from a 'B2-style' descriptive sentence to the C2 professional register found in the text:
- B2 Level: The FDA rejected the application because the trial compared the vaccine to standard shots instead of high-dose ones. (Linear, actor-driven, simplistic).
- C2 Level: "This distinction arises from a prior regulatory dispute wherein the FDA initially rejected the application on the grounds that..."
What happened here?
- The 'Distinction' as Subject: The sentence doesn't start with a person; it starts with a conceptual noun (distinction). This detaches the emotion and focuses on the systemic logic.
- Prepositional Heavy-Lifting: The use of "on the grounds that" replaces the basic "because." This is the language of jurisprudence and high-level administration.
🛠 Lexical Precision: The 'Surgical' Vocabulary
C2 mastery requires words that do not just describe, but categorize. Note these specific choices from the text:
- Bifurcated: Instead of saying "two different paths," the author uses bifurcated. This implies a formal, structural split.
- Contingent upon: A high-level alternative to "depends on," specifically used in legal and contractual contexts.
- Temporal efficiency: Rather than saying "it is faster," the author nominalizes the concept of time (temporal) and the quality of the process (efficiency).
🎓 Scholarly Synthesis
To replicate this style, the student should practice "The Noun Shift."
Instead of writing: "The company changed how they make vaccines, so they can deploy them faster," Write: "The transition in manufacturing methodology has facilitated an increase in temporal efficiency, allowing for more precise alignment with viral strains."
Key Takeaway: C2 English is not about 'complex' words, but about conceptual density. By transforming verbs into nouns, the writer shifts the focus from who is doing what to how the system operates.